

**APPENDIX X**

**[http://www.pjbpubs.com/animal\\_pharm/index.htm](http://www.pjbpubs.com/animal_pharm/index.htm)**

ld put the old Purina back in.

s is an independent com- as spun off to shareholders *Feedstuffs*, April 6, 1998).

headquartered in St. Louis, op- ants and produced 7.1 mil- animal feed last year, making l virtually tied as the largest rs in the U.S. Purina had sales \$998.7 million. ■

## t of GM crops/ From p. 1

a fewer farmer-feeders who own GM grain. Many con- ck feeders must buy rations npany with which they have Dther feedlots may be reluc- direct from the farm because of aflatoxin testing and afla- nity programs.

ck feeders may not be able off-hour deliveries of grain est.

es of the unapproved corn ght add transportation costs uyers.

ig plans with forward con- n program loans would be

evators may not be able to unapproved corn varieties taminating other facilities, direct onto trains would ractical.

s in the GMO war may go companies. Last week, the *Times* reported that a multi- r antitrust lawsuit is being nst the world's largest life npanies. The lawsuit is be- ted by Jeremy Rifkin's -based Foundation on Eco- ds and the National Farm ition (NFFC).

r of NFFC confirmed that ps are working on identi- ffs for the suit, which is

NO. (DIAMOND, which is coming on stream this month [*Feedstuffs*, Aug. 30], is the newest pork house in North America.)

Maple Leaf, headquartered in Toronto, Ont., is one of Canada's larg- est food processors with interests in fresh and further-processed beef, pork, poultry and seafood, as well as com- modity processing. The company had 1998 sales that totaled \$3.2 billion (Ca- nadian). ■

expected to be filed later this year.

The suit is expected to challenge the legality of "leasing" genetics to farm- ers for use for just one season. The use of the "terminator" gene technology is also expected to be an issue in the case.

The *Financial Times* reported that some 20 U.S. law firms had agreed to take the case on a "no-win, no-fee" basis. ■

## BI, Fort Dodge settle patent dispute

ST. JOSEPH, MO. — Boehringer Ingelheim Vetmedica, Inc. (BI), and Fort Dodge Animal Health, a division of American Home Products Corp., announced Sept. 16 that they have agreed to a settlement of a patent dispute in- volving Fort Dodge's introduction of Suvaxyn PRRS, a vaccine used to pro- tect pigs from infection with porcine reproductive and respiratory syndrome (PRRS).

Without admitting any liability, Fort Dodge announced it will cease for the present time manufacturing and selling of the product in the U.S.

As part of the research-based Ameri- can Home Product group of companies, Fort Dodge said it values and supports the U.S. patent system. Fort Dodge said it will continue its research efforts to commercialize its own PRRS vaccine. ■

for major comm- clude aid for farm disasters this ye- the Northeast and

For disaster r- gested Congres- similar to those i- ers were comp- yields were less average. The U.S. culture estimates cost \$800 millio

Because both have already ap- propriations bil- amount of farm

## New Eu

■ By IAN ELLIOTT  
Feedstuffs Corresp

Romano Prodi commissioners l- fore the Europ- bringing new le- pean Union an- hiatus during w- mission consid- housekeeping n

Prodi, a forme- becomes presic- Commission. Th- the executive fi- operating much- governments.

Prodi's new c- until Jan. 22, 2- round of Worl- (WTO) talks an- form of the EU' Policy (CAP).

Development- areas will be m- bers of Prodi's- one returning. Austria returns- riculture and fis- sponsibility for- France takes cl

The following veterinary products were recently granted approval by the Italian regulatory authority and appeared in Italy's Official Journal during July and August.

Manufacturer/ Distributor	Product	Indication
Ascor Chimici	Amoxicilina Triltrato 80% (amoxicillin)	Treatment of bacterial infections due to amoxicillin-sensitive micro-organisms in broilers
Chassot	Cefaseptin (cephalexin)	Tablets for use in dogs against all infections due to cephalixin-sensitive micro-organisms
Chemifarma	Tiam Oxi (tiamulin + oxytetracycline)	Broad-spectrum medicated premix for use in pigs
Farmaceutici Gellini	Suivac PE	Inactivated vaccine for the prevention of <i>Mycoplasma hyopneumoniae</i> in pigs
Filozoo	Trimethoprim 2% Sulfade- metossina 10% (trimethoprim + sulphadime- thoxide)	Treatment & control of bacterial infections sensitive to sulphur-based products in pigs, calves & broilers
Hoechst Roussel Vet	Hostacyclin LA (oxytetracycline)	Treatment of bacterial infections due to oxytetracycline-sensitive micro-organisms in cattle, pigs & sheep
Industria italiana integratori-Trei	Doxipan Mix (doxycycline)	Medicated premix for use against doxycycline-sensitive Gram-positive & Gram-negative infections in pigs, particularly respiratory infections
Intervet	Bovilis IBR+PI3 Inact	Inactivated cattle vaccine for use against infectious bovine rhinotracheitis & bovine parainfluenza
Janssen-Cilag	Flubenol Easy (flubendazole)	Treatment of ascarids, hook- & whipworms in dogs
Vétoquinol	Marbocyl 2% (marbofloxacin)	Treatment of marbofloxacin-sensitive <i>Pasteurella multocida</i> , <i>P. haemolytica</i> & <i>M. bovis</i> in calves & marbofloxacin-sensitive strains of <i>pleuropneumoniae</i> , <i>M. hyopneumoniae</i> , & <i>P. multocida</i> in fattening pigs

## News in brief

### Yarrah's organic pet food in UK

UK company Yarrah (Bath, Avon) has launched a range of organic cat and dog foods that contain organic chicken meat and are guaranteed free of hormones, pesticides, and artificial fertilisers. The range, only available in the UK, has already been taken up by the Sainsbury's, Tesco's and Waitrose supermarket chains, and the pet superstore chain Petsmart. "Consumer response has been excellent," said a company spokesperson.

Heska UK has been granted an EU authorisation for Heska Perioceutic (doxycycline hyclate), a dental gel for the treatment of periodontal disease in dogs. It is applied subgingivally in the periodontal pockets of affected teeth, following teeth cleaning, and is supplied in boxes of three or ten units, each comprising one syringe of polymer solvent and one of the active ingredient in powder form. It was launched in the US in 1997 (Animal Pharm No 386, p 18).

Perioceutic was initially developed by Atrix Laboratories (Fort Collins), which is primarily active in human medicine. Atrix needed a strong marketing partner for the product and saw Heska as "a natural fit".

Heska Corporation (Fort Collins, Connecticut) reported record revenues for the quarter ended June 30th 1999, with total revenues reaching \$12.9 million, an increase of 40% relative to the equivalent period in 1998. The company's first-half sales showed a similar percentage increase, reaching \$23.9 million compared with \$17.1 million in 1998. Net loss for the first six months of this year was \$14.8 million, approximately \$5 million less than for the first half of 1998.

## News in brief

### Intervet's Caninsulin in France

Intervet's canine diabetes product, Caninsulin, is now licensed in France. The product, based on an insulin extracted from the pig's pancreas, has been available in other countries, including the UK, Germany, and Australia, for several years, but its French launch has been delayed by a lengthy regulatory process. "It is the only insulin available for veterinary use in France," said product manager Nathalie Pham, who confirmed that Intervet is now planning to develop insulin compounds to treat cats. Diabetes is estimated to affect 1% of dogs in France.

### Intervet PRRS vacc awaits Dutch registration

Intervet is awaiting marketing authorisation for a new PRRS vaccine in the Netherlands, reports Boerderij. PorcilisPRRS will be the second vaccine against porcine reproductive and respiratory syndrome to appear on the Dutch market, joining Boehringer Ingelheim's Ingelvac PRRS MLV. The Intervet vaccine is initially expected only to be registered for use in fattening pigs. It incorporates attenuated live virus derived from a European strain, although a combination vaccine against both European and American strains is said to be in development, which Intervet claims will offer broader protection than using one strain only. The Boehringer Ingelheim product features an American strain but, according to a spokesman, confers sufficient protection against several virus strains.

### Boe Ing and Fort Dodge settle patent dispute

Boehringer Ingelheim Vetmedica and Fort Dodge Animal Health have agreed on the settlement of a patent dispute involving Fort Dodge's introduction of Suvaxyn PRRS, a vaccine for porcine reproductive and respiratory syndrome (PRRS). While admitting no liability, Fort Dodge has decided to suspend manufacturing and sales of the product within the US. Fort Dodge has said that it values and supports the US patent system as a means of fostering innovation in its own activities as well as those of other research organisations. The company also said that it would be continuing its research towards the commercialisation of its PRRS vaccine in the US in the future.